Management Team consists of the two company founders, Dr. Stephen Gillies
and Mr. Jason Walsh, together with a virtual team of experienced biological research and development experts.
Stephen D. Gillies, Ph.D, President and CEO
Dr. Gillies is an expert in the creation and development of recombinant antibodies and immunotherapy.
He is inventor of core platform technologies, immunocytokines and Fc-X, for which there are several clinical projects in development with various
pharmaceutical companies, research institutes, and government agencies.
Prior to founding Provenance Biopharmaceuticals Corp., Dr Gillies led all scientific and business endeavors of Lexigen Pharmaceuticals Corp. since its founding in 1992 as Fuji Immunopharmaceuticals Corp.
In this capacity, he
was responsible for numerous funding activities and corporate partnerships,including the acquisition of the Company by Merck KGaA
After Lexigen's acquisition in 1999, Dr. Gillies had the additional responsibility of overseeing Global Oncology Pre-clinical research for Merck KGaA.
Previously, he was vice president of research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein.
As a postdoctoral fellow at the Massachusetts Institute of Technology, he identified the first cellular enhancer sequences that were found to be critical for the regulation of antibody expression.
This discovery proved a key part of the commercial success of Erbitux, a cancer drug marketed by Imclone Systems Inc.
, Bristol Myers Squibb
, and Merck KGaA
As part of his
recombinant antibody project work, Dr. Gillies
invented and implemented the immunocytokine technology, and leveraged through his
academic network, the first proof of principle of this approach.
Through support of the National Cancer Institute
and clinicians in both the US and Germany the first clinical trials were conducted.
During the course of his
scientific career, Dr. Gillies
led multiple therapeutic candidates into clinical development for HIV/AIDS and cancer.
These include engineered antibodies, NCEs and immunocytokines.
Dr. Gillies received his M.S. degree and Ph.D. from the College of Medicine and Dentistry, Rutgers University and his B.S. degree from the University of Massachusetts, Amherst.
Andrew Raubitschek, MD. Chairman of the Department
of Cancer Immunotherapeutics
and Tumor Immunology at the City of Hope National Medical Center
in Duarte, California: Dr. Raubitschek has had a strong interest in immunocytokines for many years and has recently collaborated with Dr. Gillies
to create and develop the DI-Leu16-IL2 immunocytokine.
Walker Professor in the Departments of Pediatrics, Human Oncology & Genetics, Head of Pediatric Hematology-Oncology, and Associate Director (for translational research) of the Paul P. Carbone Comprehensive Cancer Center
, at the University of Wisconsin - Madison
: Dr. Sondel is a long-term collaborator of Dr. Gillies
working both on pre-clinical proof-of-principle studies, as well as a main driver of the Phase I and II studies of the anti-GD2 targeting immunocytokine, hu14.18- IL2.
Prior to work with immunocytokines, Dr. Sondel has been involved in the early clinical studies of IL-2 and worked with Dr. Gillies
in the early U.S. studies of the parent antibody, ch14.18, in neuroblastoma and melanoma patients.
Drs. Sondel and Gillies
are coauthors on more than 10 peer-reviewed journal articles.
Professor in the Department of Immunology and Microbial Science at the Scripps Research Institute
in La Jolla, California: Dr. Gillies
and Dr. Reisfeld have been collaborators for more than twenty years.
In fact, the first immunocytokines created by Dr. Gillies
utilized antibodies (14.18 and KS-1/4) first isolated in Dr. Reisfeld's laboratory in the 1980's.